September 10, 2019

Building Momentum Toward First-in-Human Clinical Trials

Morphocell Technologies Inc. held a successful pre-pre-Clinical Trial Application (CTA) meeting with Health Canada in August 2019.

Health Canada agreed in principle to the proposed non-clinical plan in support of a first in human clinical trial. The discussion focused on the acceptability of our non-clinical and quality development plans for ReLiver®ELT. A high-level discussion on the potential design of our first-in-human clinical trial that provided great direction for fine-tuning our approach.


Health Canada’s Biologics and Genetic Therapies Directorate and Medical Devices Bureau offered valuable guidance on data that would be considered acceptable to support our initial CTA.

The Morphocell team is looking forward to using Health Canada’s input to further refine ReLiver®ELT development plans. More to come – follow us on Twitter for updates.

+1 (514) 345 4931 ext. 7879

c/o CHU Sainte-Justine Research Center
3175 Ch. Côte-Sainte-Catherine
Montreal, QC, H3T 1C5

© Copyright Morphocell Technologies Inc 2019

  • i_mail